dHACM - MiMedx
Alternative Names: AmnioFix®; Amniotic cell therapy - MiMedix; Dehydrated human amnion/chorion allograft; Dehydrated human amnion/chorion membrane; Dehydrated human amniotic membrane; Dehydrated human amniotic membrane micronised; Human amniotic membrane allograft - MiMedix; mdHACM; Micronised dehydrated human amniotic membrane; Micronised tissue allografts - MiMedx; Micronised-dHACM; Micronized dHACMLatest Information Update: 30 Jan 2024
At a glance
- Originator MiMedx
- Class Cell therapies; Tissue extracts
- Mechanism of Action Cell replacements; Cell stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Plantar fasciitis; Tendinitis
- Phase II Wounds
- Suspended Osteoarthritis
- No development reported Ischaemia; Shoulder injuries
Most Recent Events
- 15 Dec 2023 MiMedx terminates a phase IIb trial for Osteoarthritis in the USA (Parenteral, Injection) due to sponsor's decision(NCT05796765)
- 20 Jun 2023 Suspended - Phase-II for Osteoarthritis (In the elderly, In adults) in USA (Parenteral)
- 20 Jun 2023 Suspended - Phase-III for Osteoarthritis (Intra-arterial)